Eli Lilly (Painful Distal Sensory Polyneuropathy): Effect of LY4515100 versus Placebo in Participants with Painful Distal Sensory Polyneuropathy

posted on October 7, 2026

Sponsor Name: Eli Lilly and Company
Regulatory Agency Identifier Numbers: IND: 183110; EU trial number: 2026-527414-23-00

Protocol Title: A Phase 2, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled, Dose-Ranging Study to Evaluate LY4515100 in Participants with Painful Distal Sensory Polyneuropathy

Brief Summary: The purpose of this study is to assess how different doses of LY4515100 compare with placebo in improving pain intensity in participants with painful DSP.

Study details include:

  • The study duration will be up to 20 weeks.
  • The treatment duration will be up to 12 weeks.
  • The visit frequency will be every 2 weeks from Visit 3 to Visit 9, including in-clinic and telehealth visits.